Stephen J. Forman

City Of Hope National Medical Center — United States

Medicine · Health Sciences

127h-index59.4kcitations1.8kworks3.82yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(489), Hematopoietic Stem Cell Transplantation(429), Acute Lymphoblastic Leukemia research(272), Acute Myeloid Leukemia Research(256), Lymphoma Diagnosis and Treatment(253)

Publications1.8k total

Profile of a Pioneer: Karl G. Blume

Transplantation and Cellular Therapy·2026Open Access

Supplementary Table S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplementary Table S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Supplementary Table S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

2025Open Access

Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

Bone Marrow Transplantation·2025Open Access

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Blood·2025

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Blood·2025Open Access

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Blood·2025Open Access

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood·2025Open Access

Chronic myeloid leukemia (CML) evolution is not encoded in single-cell microstates, but emerges from population-level macrostates

Blood·2025Open Access

Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma

Blood·2025

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Blood·2025Open Access

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Blood·2025Open Access

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

Blood·2025Open Access

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood·2025

page 1 of 90Next →

Frequent Co-authors

Ravi Bhatia(15), Michael C. Jensen(13), Christine E. Brown(10), Julie R. Ostberg(8), Andrew Raubitschek(7), Renate Starr(6), Anthony S. Stein(6), Liton Francisco(6), Jamie R. Wagner(5), Saul J. Priceman(5), Xiuli Wang(5), Behnam Badie(5), Stanley R. Riddell(5), David S. Snyder(5), Laurence J.N. Cooper(5), Brenda Aguilar(5), Heehyoung Lee(5), Andreas Herrmann(5), Hua Yu(5), Araceli Naranjo(4)